Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo controlled trial

Arthritis Care and Research

Volumn 51, Issue 4, 2004, Pages 549-557

  Schnitzer, Thomas J ^a,f   Beier, Jannie ^b   Geusens, Piet ^c   Hasler, Paul ^d   Patel, Sanjay K ^e   Senftleber, Ingo ^f   Gitton, Xavier ^g   Moore, Alan ^g   Sloan, Victor S ^g   Poor, Gyula ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Private Rheumatology Practice   (Denmark)

^c HASSELT UNIVERSITY   (Belgium)

^d Felix Platter Spital   (Switzerland)

^e Adan House Surgery   (United Kingdom)

^f Novartis Pharma AG ^*  (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h National Institute of Rheumatology Budapest   (Hungary)

Author keywords

Diclofenac; Lumiracoxib; Osteoarthritis; Pain relief

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTHRITIS; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; OSTEOARTHRITIS; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 19244365254     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20525     Document Type: Article

References (51)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Simon LS. Osteoarthritis: a review. Clin Cornerstone 1999;2: 26-37.
3. Hinton R, Moody RL, Davis AW, Thomas SF. Osteoarthritis: diagnosis and therapeutic considerations. Am Fam Physician 2002;65:841-8.
4. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000;60:6-8.
5. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997;11:817-34.
6. Altman RD, Kochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15.
7. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for nonsteroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998;317:526-30.
8. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
9. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44:1587-98.
10. Altman RD, The IAP Study group, Miami, FL. Ibuprofen, acetaminophen and placebo in osteoarthritis of the knee: a six-day double-blind study. Arthritis Rheum 1999;42 Suppl 9:S404.
11. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: an overview of epidemiological studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
12. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110:20S-7S.
13. Vane J, Botting R. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987;1:89-96.
14. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. Drug Ther 2001;345:433-42.
15. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
16. Bensen WG, Flechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized, controlled trial. Mayo Clin Proc 1999;74:1095-105.
17. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
18. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
19. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos Vargas R, Davis B, et al, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
20. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87.
21. Day R, Morrison B, Luza A, Castenado O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
22. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors: the rheumatologist's perspective. Clin Exp Rheumatol 2001;19 Suppl 25:S15-22.
23. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
24. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg K, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
25. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
26. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: a systematic review of randomised control trials. BMJ 2002;325:619-23.
27. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
28. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs. BMJ 2002;325:624-7.
29. FDA. Labeling changes for arthritis drug celebrex. Accessed April 12, 2004. URL: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01151.html.
30. FDA. FDA approves new indication and label changes for the arthritis drug, Vioxx. Accessed April 12, 2004. URL: http://www.fda.gov/bbs/topics/ ANSWERS/2002/ANS01145.html.
31. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Rev 2004;32:566-71.
32. Fricke J, Zelenakas K, Jayawardene S, Manning D. Efficacy of COX189 compared to rofecoxib in the treatment of postoperative dental pain: a double-blind, randomized, placebo-controlled trial. World Congress on Pain (WCP); 2002 Aug 17-22; San Diego, California. Abstract 953-P223.
33. Zelenakas K, Fricke J Jr, Jayawardene S, Kellstein D. Analgesic efficacy of single oral doses of lumiracoxiband ibuprofen in patients with postoperative dental pain. Int J Clin Pract 2004;58:251-6.
34. Altman R, Asch E, Bloch G, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
35. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
36. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
37. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50:1096-121.
38. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-60.
39. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
40. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995;56 Suppl 1:18-22.
41. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61 Suppl 1:242 Abstract FR10300.
42. Day RO, McLachlan AJ, Graham GG, Williams KM. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999;36:191-210.
43. Benson MD, Aldo-Benson M, Brandt K. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum 1985;5 Suppl 1:65-7.
44. Fowler PD, Shadforth MF, Crook PR, John VA. Plasma and synovial fluid concentrations of diclofenac sodium and its major hydroxylated metabolites during long-term treatment of rheumatoid arthritis. Eur J Clin Pharmacol 1983;25:389-94.
45. Gaucher A, Netter P, Faure G, Sioufi A, Schoeller JP. Passage du diclofénac sodium dans le liquide synovial. Thérapie 1983;38:431-4.
46. Sioufi A, Schoeller JP, Schwarzberg C, Colussi D, Mangoni P. Présence du diclofénac dans le plasma et le liquide synovial au cours de diverses affections rheumatismales. Gaz Méd Fr 1984;91:88-9.
47. Köhler G, Mohing W. Zur Kinetik von diclofenac-Na in Plasma und Synovialflüssigkeit. Aktuelle Rheumatol 1980;5:151-5.
48. Liauw H, Waiter S, Lee L, Ku E. Effects of diclofenac on synovial eicosanoid product formation in arthritic patients. J Clin Pharmacol 1985;25:456.
49. Scott G, Rordorf C, Milosavljev S, Ferber G. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis. Ann Rheum Dis 2002;61 Suppl 1:128 Abstract THU0233.
50. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Pharmacokinet 2004;43:467-78.
51. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.